MOTS-c vs AOD-9604: two peptides that don't do the same job

Last updated 2026-07-24

What is MOTS-c and what is AOD-9604, in plain terms?

MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA, in the region overlapping the 12S rRNA gene. It's not a synthetic drug fragment; it's a molecule your own cells already make, released under metabolic stress like exercise or fasting. The foundational 2015 paper in Cell Metabolism showed MOTS-c injections improved insulin sensitivity and reduced diet-induced and age-related obesity in mice ^[1]. Since then it's been shown to translocate to the cell nucleus and directly regulate gene expression under metabolic stress, which is unusual behavior for a peptide this small ^[2]. AOD-9604 is a different kind of molecule entirely. It's a synthetic fragment of human growth hormone, specifically amino acids 176-191 of the HGH sequence, modified to isolate the fat-metabolizing (lipolytic) effect of growth hormone while trying to strip out the effects on blood sugar and tissue growth. It was originally developed by a biotech company as an anti-obesity drug candidate and tested in human clinical trials in the 2000s. So the starting point matters: MOTS-c is a naturally occurring mitochondrial signal being studied for what it already does in the body. AOD-9604 is an engineered fragment of a hormone, built by chemists trying to cut a therapeutic effect out of a molecule (HGH) that has other effects they wanted to avoid. Different origin, different mechanism, different research history. If you want the deeper background on MOTS-c biology specifically, the mots-c hub page walks through the discovery history and open questions in more depth.

How do MOTS-c and AOD-9604 actually work?

MOTS-c's proposed mechanism runs through AMPK activation and, more surprisingly, direct nuclear action. A 2018 Cell Metabolism paper found MOTS-c translocates into the nucleus during metabolic stress and regulates antioxidant response gene expression there, acting more like a transcriptional regulator than a classic peptide hormone ^[2]. More recent mechanistic work found MOTS-c binds and activates casein kinase 2 (CK2) in skeletal muscle to modulate muscle function, a distinct pathway from the nuclear translocation story ^[3]. A 2019 BioEssays review frames MOTS-c as a mitochondrial-encoded regulator that talks directly to the nucleus, which is part of why researchers find it interesting beyond metabolism alone ^[4]. AOD-9604's proposed mechanism is much narrower by design: it's meant to trigger lipolysis (fat breakdown) and inhibit lipogenesis (fat storage) in adipose tissue, mimicking the fat-metabolizing tail end of the growth hormone molecule without triggering the insulin-resistance or tissue-growth effects associated with full-length HGH. That's a genuinely clever design goal on paper. Whether it delivers meaningfully in humans is the open question, and it's the same question regulators and researchers have been stuck on for close to two decades. The mechanisms don't overlap in any meaningful way. One is a mitochondrial signal with a nuclear gene-regulation angle and emerging roles in muscle, bone, and even antiviral and cancer-suppression contexts. The other is a single-purpose fat-metabolism fragment derived from a growth hormone sequence.

What does the human and animal evidence actually show for each?

This is where you need to slow down, because most of what circulates online for both peptides overstates what's been shown. MOTS-c: the evidence base is almost entirely rodent and cell-culture work. The original 2015 Cell Metabolism paper is a mouse study showing reduced obesity and improved insulin resistance with MOTS-c administration ^[1]. A 2022 Pharmacological Research paper found MOTS-c improved hyperglycemia and insulin resistance in a gestational diabetes mellitus model ^[5]. A 2023 Metabolites paper reviewed MOTS-c's role preventing metabolic disorders broadly, again synthesizing mostly preclinical data ^[6]. A 2023 Frontiers in Endocrinology review calls MOTS-c 'a promising mitochondrial-derived peptide for therapeutic exploitation,' which is an honest way to say: interesting target, not yet a proven human therapy ^[7]. A 2025 paper in Experimental & Molecular Medicine found MOTS-c prevented pancreatic islet cell senescence in a diabetes model, again preclinical ^[8]. There is no published randomized controlled trial in humans establishing MOTS-c's effect on weight, insulin sensitivity, or any clinical endpoint. That gap is the single most important fact in this whole comparison. AOD-9604: this one actually made it into human trials, which is a real point of difference. It was tested in obesity trials in the 2000s but failed to demonstrate a statistically significant weight-loss benefit over placebo in its main program, and the sponsor did not pursue FDA approval for that indication. It has continued to be studied in other contexts (notably osteoarthritis and cartilage repair in some smaller studies) but it has never received FDA approval for any use. So AOD-9604 has more human trial exposure than MOTS-c, but the trial it's most associated with (obesity) didn't succeed. Neither peptide is FDA-approved for any indication. You can confirm approval status yourself in the Drugs@FDA database, which lists every approved drug product in the US; neither MOTS-c nor AOD-9604 appears there as an approved product ^[9].

Is MOTS-c really 'exercise in a pill'?

No, not based on what's actually been published, and this framing deserves pushback every time it shows up in marketing copy. The honest version: MOTS-c is released during exercise as part of a stress-response system called mitohormesis, where mild mitochondrial stress triggers adaptive, protective signaling. A 2022 review in Diabetes & Metabolism Journal lays out this exercise-mitohormesis-MOTS-c connection directly, describing MOTS-c as part of the signaling cascade activated by exercise rather than a substitute for it ^[10]. A 2021 review in Biochimica et Biophysica Acta looked specifically at mitochondrial-derived peptides and exercise, again characterizing MOTS-c as a downstream signal of exercise stress, not a replacement ^[11]. That's a meaningfully different claim than 'take this peptide and get the metabolic benefits of exercise without moving.' Nobody has published a human trial testing whether injected MOTS-c reproduces the metabolic benefits of an actual exercise program in people who don't exercise. The rodent obesity and insulin-resistance data are real and interesting ^[1], but mice given a peptide injection in a lab are not the same as a sedentary human taking a compounded product and skipping the gym. If a company's sales copy uses 'exercise mimetic' to mean 'skip the workout,' that's marketing outrunning the data, full stop. AOD-9604 doesn't get the exercise-mimetic pitch typically; its marketing angle is usually 'fat-burning without the growth hormone side effects,' which has its own evidence problems given the mixed obesity trial history.

MOTS-c vs AOD-9604: side-by-side comparison

The practical read: MOTS-c has a wider and arguably more mechanistically interesting research footprint right now, spanning muscle, bone, lung, liver, and even oncology contexts. AOD-9604 has a narrower, older, and more human-trial-tested footprint that didn't produce a clean win.

What does the research say about MOTS-c and muscle, compared to AOD-9604's fat-focused claims?

MOTS-c has a growing body of muscle-specific preclinical work that AOD-9604 doesn't really have an equivalent for. A 2021 paper in American Journal of Physiology-Endocrinology and Metabolism found MOTS-c reduced myostatin and muscle atrophy signaling in animal models ^[20]. A 2022 Peptides paper found MOTS-c promotes muscle differentiation in vitro ^[21]. A 2024 paper in the same physiology journal found MOTS-c attenuated immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration into muscle tissue ^[15]. And the 2024 iScience paper on CK2 binding specifically ties MOTS-c to direct modulation of skeletal muscle function at the molecular level ^[3]. That's a coherent, if entirely preclinical, story: MOTS-c shows up repeatedly in muscle-preservation and muscle-function research, more than fat metabolism. AOD-9604's research focus has stayed narrower, centered on fat cell lipolysis and lipogenesis inhibition, with some separate exploration in cartilage and joint contexts. It doesn't have a comparable muscle-preservation literature. If your interest is specifically in muscle-related mechanisms, the mots-c dosage and mots-c peptide injection pages cover how researchers typically administer it in study protocols, which is worth understanding before assuming any of this translates to a home injection routine.

Is either peptide legal to buy, and what does 'research use only' actually mean?

Neither MOTS-c nor AOD-9604 is FDA-approved, and that status matters more than most sellers let on. Under US compounding law, pharmacies can legally prepare certain drug products from bulk substances under specific conditions set out in 21 U.S.C. 353a ^[22]. For 503A pharmacies, FDA maintains a bulks list under 21 CFR 216.23 ^[12], and for 503B outsourcing facilities there's a separate bulks list under 21 CFR 216.24 ^[13]. FDA also maintains a running list of bulk drug substances nominated for compounding consideration ^[23]. Neither MOTS-c nor AOD-9604 currently sits on the approved 503A or 503B bulks lists, which is a real constraint on how they can be legally compounded and dispensed as human drug products in the US. That's exactly why you see both peptides sold labeled 'for research use only, not for human consumption.' That label is doing real legal work, more than covering liability theater. Under 21 CFR 201.128, a product's 'intended use' is determined by how it's actually marketed and represented, more than by the label text ^[24]. So a research-use label paired with dosing charts and injection instructions aimed at individual consumers sits in a legally murky spot, and it's not something a buyer should assume protects them. A recent 2026 Sports Medicine paper specifically reviewed the safety and efficacy landscape for approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance, which is worth reading if you're weighing this category generally rather than just MOTS-c or AOD-9604 specifically ^[25]. If you're going to explore either compound, doing it through a provider-reviewed pathway rather than an anonymous research-chemical vendor is the difference between informed decision-making and gambling on a vial with no chain of custody. MOTS-c Co works with a provider-reviewed sourcing route through motscco.com, fulfilled by a licensed pharmacy partner, specifically because unregulated vendor purity and dosing accuracy are real, documented problems in this market.

What are the safety concerns for MOTS-c vs AOD-9604?

Honest answer: safety data for both, in humans, is thin. For MOTS-c, most safety-relevant signals come from mechanistic and disease-model studies rather than dedicated toxicology trials in healthy humans. Some of what's been published actually raises questions worth sitting with rather than dismissing. A 2018 Rejuvenation Research paper titled 'Mitochondrial-Derived Peptides Exacerbate Senescence' is a reminder that this peptide family's effects aren't uniformly protective in every context studied ^[26]. Separately, a 2024 paper in Advanced Science found MOTS-c suppressed ovarian cancer progression by affecting a specific ubiquitination pathway (USP7-mediated LARS1 deubiquitination) ^[16], which sounds like good news for that cancer model, but it also confirms that MOTS-c interacts with cancer-relevant cellular machinery. That's not automatically a red flag, tumor-suppressive findings are a good sign in that specific model, but it does mean MOTS-c is biologically active in pathways serious researchers watch closely, not an inert supplement. For AOD-9604, because it's derived from growth hormone, the original development goal was specifically to avoid GH's known side effects (blood sugar disruption, tissue overgrowth risk). Whether that separation is clean in practice, especially with unregulated compounded product, isn't something independently verified at scale in the public literature. For a full rundown of documented and theoretical adverse effects specific to MOTS-c, see mots-c side effects. Neither peptide has the kind of large, long-duration human safety database that approved drugs are required to generate before reaching market.

Which one has better evidence for fat loss specifically?

Neither has convincing human evidence for fat loss as a standalone outcome, but they got there differently. AOD-9604 was purpose-built and clinically tested specifically for weight loss, and it did not clear that bar in its main human trials. That's a cleaner, harder no than most peptides in this space get, because it actually went through the trial process and the result was not a win for the primary endpoint. MOTS-c's fat-related evidence comes from a different angle entirely: the 2015 Cell Metabolism mouse study showing reduced diet-induced and age-related obesity alongside improved insulin resistance ^[1], and later work in disease-specific models like gestational diabetes ^[5] and diabetic liver fibrosis, where a 2025 Scientific Reports paper found MOTS-c mimicked exercise-associated signaling to reduce liver fibrosis markers by targeting the Keap1-Nrf2-Smad2/3 pathway in an animal model ^[27]. These are legitimate, interesting findings. They are also, again, animal studies. Nobody has run the human RCT that would tell you whether MOTS-c reduces body fat percentage in people. So: AOD-9604 tried and, by the primary endpoint, didn't succeed in humans. MOTS-c hasn't been tried yet in that same rigorous way. Neither is currently a validated human fat-loss therapy, and anyone selling either one with a confident 'proven fat loss' claim is ahead of the actual literature.

Does MOTS-c or AOD-9604 have research outside of metabolism and fat loss?

MOTS-c's research footprint has expanded well beyond metabolism in the last few years, which is part of why it keeps showing up in unrelated disease-model papers. Recent examples: a 2024 Gut paper found MOTS-c has an antiviral role during hepatitis B infection through mitochondrial remodeling ^[17]; a 2024 Theranostics paper found MOTS-c helps repair plasma membrane damage by facilitating TRIM72 translocation ^[28]; a 2025 Redox Biology paper found MOTS-c attenuates lung ischemia-reperfusion injury ^[18]; a 2023 Mitochondrion paper explored it as a potential anti-pulmonary fibrosis factor ^[29]; a 2025 International Immunopharmacology paper found it reduces airway barrier dysfunction in an allergic asthma model ^[30]; and a 2025 Cardiovascular Drugs and Therapy paper reviewed its potential relevance to diabetic cardiomyopathy ^[31]. There's also emerging work on bone metabolism (2023, Frontiers in Physiology) ^[14] and cartilage degradation in osteoarthritis models (2025, Free Radical Biology & Medicine) ^[19]. That's an unusually broad research spread for a 16-amino-acid peptide, and it's exactly why researchers keep returning to it: the same molecule keeps turning up as relevant across mitochondrial stress responses in wildly different tissues. AOD-9604's literature stays much more contained to fat metabolism, with a secondary line of investigation in osteoarthritis and cartilage. It hasn't generated the same volume of mechanistically diverse findings. Breadth of preclinical interest isn't the same as clinical proof, to be clear. But it does tell you where researchers are placing their bets right now, and right now, more of those bets are on MOTS-c.

How should you actually think about choosing between them?

If you're a researcher or a genuinely informed self-experimenter weighing these two, here's the honest framing. AOD-9604 has more human trial history but a track record that includes a real, documented failure to hit its primary weight-loss endpoint. That's not nothing, it means someone actually asked the question in people and didn't get the answer they wanted. MOTS-c hasn't been asked that question in a controlled human trial yet, so its rodent and cell data, while broader in scope, remain one translational step away from telling you anything about a human outcome. Neither is FDA-approved. Neither sits on the current 503A or 503B bulk drug substances lists ^{[12] [13]}, which matters for anyone thinking about legitimate compounding pathways versus gray-market vendors. If you're going to look at MOTS-c specifically, start with dosing and administration protocols used in actual published research rather than whatever a vendor's dosing chart says, and go in through a provider-reviewed channel rather than an anonymous supplier with no quality documentation. For practical next steps on MOTS-c specifically: mots-c dosage and the mots-c 10mg dosage calculator cover how research protocols typically scale dosing, and mots-c peptide buy covers sourcing considerations in more depth than we can here.

Frequently asked questions

Is MOTS-c the same as AOD-9604?

No. MOTS-c is a naturally occurring peptide encoded in mitochondrial DNA, studied for metabolic and mitochondrial stress signaling. AOD-9604 is a synthetic fragment of human growth hormone engineered to isolate its fat-metabolizing effect. They have different origins, different mechanisms, and different research histories, and are not interchangeable despite both being marketed loosely as 'fat loss peptides.'

Which peptide has stronger evidence, MOTS-c or AOD-9604?

It depends on the bar you're using. AOD-9604 has more human clinical trial history, but its main obesity trials didn't show a significant weight-loss benefit over placebo. MOTS-c has a broader and more mechanistically detailed preclinical literature (rodent and cell studies) but no published human trial establishing a clinical benefit yet.

Is MOTS-c FDA-approved?

No. MOTS-c does not appear as an approved drug product in the FDA's Drugs@FDA database, and it is not on the current 503A or 503B bulk drug substances lists that govern legal compounding pathways. Any product sold as MOTS-c is being marketed outside the FDA-approved drug framework.

Is AOD-9604 FDA-approved?

No. AOD-9604 was studied in human obesity trials in the 2000s but did not demonstrate a significant weight-loss benefit over placebo in its main program, and it was never approved by the FDA for that or any other indication. It also does not appear on FDA's 503A or 503B bulk drug substances lists.

Is MOTS-c really an 'exercise mimetic'?

That's an overstatement of the current data. MOTS-c is released as part of the body's exercise-related stress response (mitohormesis), and reviews describe it as a downstream signal of exercise, not a substitute for it. No published human trial shows injected MOTS-c reproduces exercise's metabolic benefits in sedentary people.

Does MOTS-c help with muscle loss or atrophy?

In animal and cell models, yes: studies found MOTS-c reduces myostatin and atrophy signaling, promotes muscle cell differentiation in vitro, and attenuates immobilization-induced muscle atrophy by suppressing lipid infiltration. These are preclinical findings, not human clinical outcomes, so translate them cautiously.

Does AOD-9604 have muscle-related research like MOTS-c does?

Not to the same degree. AOD-9604's research literature stays concentrated on fat cell lipolysis and lipogenesis, with a secondary line of study in osteoarthritis and cartilage. It doesn't have the muscle-preservation-focused study base that MOTS-c has accumulated in recent animal research.

Can MOTS-c or AOD-9604 be legally compounded by a pharmacy?

Neither currently appears on FDA's 503A bulk drug substances list or 503B bulk drug substances list, the regulatory lists that govern which bulk substances pharmacies and outsourcing facilities can legally use in compounded human drug products. That status can change, so check FDA's current bulks list pages directly before assuming otherwise.

What does 'research use only' mean for these peptides?

It's a label meant to signal a product isn't intended for human use, tying to compounding and marketing law. Under FDA's intended-use framework (21 CFR 201.128), actual intended use is judged by how a product is marketed, more than the label text, so a research-use label paired with human dosing instructions doesn't necessarily resolve the legal ambiguity.

What are the main safety concerns with MOTS-c?

Human safety data is limited. Some preclinical findings, like MOTS-c's interaction with cancer-relevant ubiquitination pathways in an ovarian cancer model and a separate paper on mitochondrial-derived peptides exacerbating senescence in certain contexts, show this peptide family is biologically active in ways that deserve scrutiny, not blanket reassurance. See mots-c side effects for detail.

Has MOTS-c been studied for fat loss in humans?

No published human trial has tested MOTS-c specifically for fat loss or body composition outcomes. The obesity-related evidence comes from a 2015 mouse study in Cell Metabolism showing reduced diet-induced and age-related obesity with MOTS-c administration, which is a meaningful preclinical signal but not proof of a human effect.

Why do MOTS-c and AOD-9604 keep getting compared?

Both circulate in the same online peptide-sourcing communities, both get marketed loosely around metabolism and fat loss, and neither is FDA-approved, so they get bucketed together. Mechanistically and evidentially they're quite different: one is a mitochondrial gene-regulation peptide, the other a growth hormone fragment with a failed obesity trial history.

Does MOTS-c have research beyond metabolism, like AOD-9604 doesn't?

Yes. Recent papers have studied MOTS-c in contexts including ovarian cancer suppression, hepatitis B antiviral response, lung injury and fibrosis, allergic asthma, bone metabolism, and osteoarthritis-related cartilage degradation. AOD-9604's literature stays narrower, mostly centered on fat metabolism with some cartilage-related study.

Sources

1. Cell Metabolism, 2015 (PMID 25738459): MOTS-c injections reduced diet-induced and age-related obesity and improved insulin resistance in mouse models
2. Cell Metabolism, 2018 (PMID 29983246): MOTS-c translocates to the nucleus and regulates nuclear gene expression in response to metabolic stress
3. iScience, 2024 (PMID 39559755): MOTS-c directly binds and activates CK2 to modulate skeletal muscle function
4. BioEssays, 2019 (PMID 31378979): MOTS-c is characterized as a mitochondrial-encoded regulator that communicates with the nucleus
5. Pharmacological Research, 2022 (PMID 34798268): MOTS-c relieved hyperglycemia and insulin resistance in a gestational diabetes mellitus model
6. Metabolites, 2023 (PMID 36677050): Review synthesizing evidence that MOTS-c functionally prevents metabolic disorders in preclinical models
7. Frontiers in Endocrinology, 2023 (PMID 36761202): MOTS-c is described as a promising mitochondrial-derived peptide for therapeutic exploitation, reflecting its preliminary/preclinical status
8. Experimental & Molecular Medicine, 2025 (PMID 40855115): MOTS-c prevented pancreatic islet cell senescence in a diabetes model
9. FDA, Drugs@FDA database: Neither MOTS-c nor AOD-9604 is listed as an FDA-approved drug product
10. Diabetes & Metabolism Journal, 2022 (PMID 35656563): MOTS-c is part of the exercise-induced mitohormesis signaling cascade, not a standalone replacement for exercise
11. Biochimica et Biophysica Acta, 2021 (PMID 34520826): Review of mitochondrial-derived peptides including MOTS-c in relation to exercise physiology
12. eCFR, 21 CFR 216.23 (503A Bulks List): Defines the FDA 503A bulk drug substances list governing which substances pharmacies can legally compound with
13. eCFR, 21 CFR 216.24 (503B Bulks List): Defines the FDA 503B bulk drug substances list governing outsourcing facility compounding
14. Frontiers in Physiology, 2023 (PMID 37200834): MOTS-c has a studied role in regulation of bone metabolism
15. American Journal of Physiology-Endocrinology and Metabolism, 2024 (PMID 38170165): MOTS-c attenuated immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration in an animal model
16. Advanced Science, 2024 (PMID 39321430): MOTS-c suppressed ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination in a study model
17. Gut, 2024 (PMID 37788894): MOTS-c showed an antiviral role during hepatitis B infection via mitochondrial remodeling
18. Redox Biology, 2025 (PMID 40403491): MOTS-c attenuated lung ischemia-reperfusion injury via MYH9-dependent nuclear translocation
19. Free Radical Biology & Medicine, 2025 (PMID 41043625): MOTS-c attenuated mitochondrial dysfunction, pyroptosis, and cartilage degradation in an osteoarthritis model
20. American Journal of Physiology-Endocrinology and Metabolism, 2021 (PMID 33554779): MOTS-c reduced myostatin and muscle atrophy signaling in an animal study
21. Peptides, 2022 (PMID 35842023): MOTS-c promotes muscle differentiation in vitro
22. Cornell Law/US Code, 21 U.S.C. 353a: Establishes the legal framework for pharmacy compounding under section 503A
23. FDA, bulk drug substances nominated for use in compounding: FDA maintains a current list of bulk drug substances nominated for compounding consideration, distinct from the approved bulks lists
24. eCFR, 21 CFR 201.128: Defines how a product's intended use is determined by marketing and representation, not label text alone
25. Sports Medicine, 2026 (PMID 41966639): Reviews safety and efficacy of approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance
26. Rejuvenation Research, 2018 (PMID 30058454): Some mitochondrial-derived peptides were found to exacerbate cellular senescence in certain study contexts
27. Scientific Reports, 2025 (PMID 40425777): MOTS-c mimicked exercise-related signaling to reduce diabetic liver fibrosis markers via the Keap1-Nrf2-Smad2/3 pathway in a study model
28. Theranostics, 2024 (PMID 39267782): MOTS-c facilitates TRIM72 translocation to participate in plasma membrane repair
29. Mitochondrion, 2023 (PMID 37307934): MOTS-c is studied as a potential anti-pulmonary fibrosis factor derived from mitochondria
30. International Immunopharmacology, 2025 (PMID 40472776): MOTS-c reduced airway barrier dysfunction in an allergic asthma model via the Nrf2 pathway
31. Cardiovascular Drugs and Therapy, 2025 (PMID 40172798): Reviews MOTS-c's potential relevance to diabetic cardiomyopathy